Business Context and Reporting Period
The filing is a Form 6-K furnished in January 2023 by China Jo-Jo Drugstores, Inc., not Ridgetech Inc.; the source text identifies China Jo-Jo as the registrant. It reports unaudited results for the six months ended September 30, 2022, compared with the six months ended September 30, 2021. The company operates retail pharmacies, an online pharmacy, a pharmaceutical wholesale business, and a farming business in China. It had 111 pharmacies in Hangzhou at September 30, 2022.
Financial Highlights
| Metric | Six months ended September 30, 2022 | Six months ended September 30, 2021 |
|---|---|---|
| Revenue | $72.7 million | $78.5 million |
| Gross profit | $16.9 million | $15.4 million |
| Gross margin | 23.3% | 19.6% |
| Loss from operations | $(1.2) million | $(0.5) million |
| Operating margin | (1.7)% | (0.6)% |
| Net loss | $(0.6) million | $(0.3) million |
| Net loss per diluted share | $(0.13) | $(0.08) |
| Net cash provided by operating activities | $1.1 million | $0.5 million |
- Cash and cash equivalents were $14.1 million; restricted cash was $15.3 million. Combined cash and restricted cash was $29.5 million at September 30, 2022, down from $35.3 million at March 31, 2022.
- Total current assets were $72.1 million versus current liabilities of $71.4 million, resulting in working capital of $0.7 million and an approximate current ratio of 1.0.
- Current obligations included $27.6 million of notes payable, $29.3 million of trade accounts payable, $5.1 million of current operating lease liabilities, and $0.5 million of current long-term loan payable. Long-term operating lease liabilities were $8.5 million; no long-term loan payable was reported.
- Total liabilities were $79.8 million and total equity was $21.9 million at September 30, 2022.
- Investing activities used $0.1 million, while financing activities used $3.0 million. Financing included $29.2 million of proceeds from notes payable, $32.2 million of note repayments, and $1.5 million of proceeds from shares and warrants.
Material Changes Versus the Prior Comparable Period
- Revenue declined $5.8 million, or 7.3%, primarily because wholesale revenue fell $9.0 million, or 36.8%, to $15.4 million. Management attributed the decline partly to the departure of experienced sales personnel.
- Retail pharmacy revenue increased 7.1% to $43.3 million, and online sales increased 2.5% to $14.0 million. Retail sales represented 59.5% of total revenue.
- Gross profit increased 9.9% and gross margin expanded to 23.3%, principally because of stronger retail margins and product mix changes. Retail gross margin increased to 31.7% from 28.5%.
- Selling expenses increased 9.3% to $14.5 million, including approximately $0.4 million for government-requested nucleic acid testing activities and $0.7 million of additional third-party online-platform service fees.
- General and administrative expenses increased 39.9% to $3.6 million, substantially reflecting approximately $1.7 million of equity-based compensation for 850,000 shares issued in April 2022.
- The company recorded a $3.4 million foreign-currency translation loss, compared with a $0.2 million translation gain in the prior period, reducing total equity and producing comprehensive loss of $4.0 million.
- Shares outstanding increased to 5.34 million from 3.48 million at March 31, 2022, due to incentive share issuance, sale of shares and warrants, and fractional shares issued in connection with a reverse stock split.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide quantitative revenue, earnings, or cash-flow guidance.
- Management stated that COVID-19 reduced customer visits but accelerated online and O2O ordering. It characterized the operational impact as temporary, while noting that the Omicron outbreak in late 2022 temporarily increased demand for medical products.
- Local National Healthcare Security Administration budget controls and competitive conditions pressured reimbursement-related sales. Management is expanding merchandise categories and emphasizing cash sales and higher-margin products.
- Wholesale performance remains exposed to salesperson turnover, limited access to hospitals, and low-margin competition. The farming segment generated no revenue during either comparative period.
- The company had limited working-capital headroom, a substantial reliance on short-term notes payable and trade credit, and declining total cash and restricted cash.
- Management incorporated the risk factors from its Form 20-F for the year ended March 31, 2022 and cautioned that forward-looking statements may differ materially from actual results. The filing text does not provide a clear additional commitment or contingency amount beyond the balance-sheet disclosures.
Investor Verification Checklist
- Confirm the registrant identity: the supplied filing names China Jo-Jo Drugstores, Inc., while the request metadata names Ridgetech Inc.
- Verify the composition, availability, and restrictions on the $15.3 million of restricted cash.
- Review maturity dates, renewal requirements, and liquidity risks for the $27.6 million of notes payable and other current obligations.
- Assess whether the improved gross margin is sustainable and whether the wholesale revenue decline and salesperson departures have continued.
- Examine the terms and potential dilution associated with the 850,000 incentive shares and the shares and warrants sold for $1.5 million.
- Review subsequent events, COVID-related developments, regulatory changes affecting medical reimbursement, and the risk factors incorporated by reference from the 2022 Form 20-F.